Variable | OR CD4 (1: < 200 cells/mm3) All periods | OR CD4 (1: < 200 cells/mm3) 2008–2012 | OR CD4 (1: < 200 cells/mm3) 2013–2017 |
---|---|---|---|
Period of diagnosis (reference 2008–2012) | |||
2013–2017 | 0.96** (0.93, 0.98) | ||
Gender (reference female) | |||
Male | 1.28** (1.24, 1.33) | 1.33** (1.27, 1.40) | 1.26** (1.20, 1.32) |
Transgender | 0.94 (0.77, 1.15) | 1.09 (0.81, 1.47) | 0.84 (0.64, 1.10) |
Age group (reference 18–29) | |||
30–39 | 1.85** (1.79, 1.90) | 1.66** (1.59, 1.73) | 2.00** (1.92, 2.08) |
40–49 | 2.24** (1.79, 1.90) | 1.87** (1.78, 1.97) | 2.59** (2.47, 2.72) |
50–59 | 2.43** (2.30, 2.56) | 1.98** (1.82, 2.1) | 2.83** (2.63, 3.04) |
> 60 | 2.34** (2.13, 2.57) | 1.79** (1.56, 2.05) | 2.87** (2.53, 3.25) |
Region (Mexico City) | |||
Central East | 1.16* (1.08, 1.26) | 1.50** (1.34, 1.67) | 0.90 (0.80, 1.01) |
Central West | 0.89* (0.82, 0.96) | 1.16* (1.04, 1.29) | 0.68** (0.61, 0.76) |
Northwest | 0.97 (0.89, 1.05) | 1.28** (1.14, 1.43) | 0.74** (0.66, 0.86) |
Northeast | 1.06 (0.97, 1.16) | 1.49** (1.32, 1.68) | 0.77** (0.68, 0.86) |
South | 1.21** (1.12, 1.31) | 1.55** (1.39, 1.74) | 0.94 (0.84, 1.05) |
Type of health facility (reference hospital/National Institute) | |||
CAPASITS | 0.89* (0.86, 0.93) | 0.84** (0.80, 0.89) | 0.93* (0.89, 0.99) |
Specialized clinics | 0.64** (0.60, 0.69) | 0.70** (0.63, 0.78) | 0.56** (0.50, 0.62) |
Index of marginalization (reference low) | |||
Medium | 1.07 (0.95, 1.20) | 0.92 (0.77, 1.10) | 1.17** (1.00, 1.37) |
High | 1.23** (1.12, 1.35) | 0.99 (0.86, 1.15) | 1.43** (1.27, 1.62) |
Observations | 107,018 | 47,705 | 59,313 |
C-Statistics | 0.6158 | 0.6009 | 0.6165 |